101 Seaport Boulevard, 7th Floor
About Orchard Therapeutics
Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.
Orchard’s portfolio of ex vivo autologous gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first ex vivo autologous gene therapy approved by the EMA in 2016, three advanced registrational studies for metachromatic leukodystrophy (MLD), ADA-SCID and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD), transfusion-dependent beta-thalassemia (TDT) and mucopolysaccharidosis type I (MPS-I), as well as an extensive preclinical pipeline.
The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.
Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London and Boston.
112 articles with Orchard Therapeutics
Yposkesi Has Been Selected by Orchard Therapeutics to Produce Lentiviral Gene Therapy Vectors For Clinical Trials
As part of this partnership, Yposkesi will produce lentiviral vector batches to meet Orchard's needs for clinical trials in primary immune deficiencies including X-linked chronic granulomatous disease.
Orchard Therapeutics and Généthon Announce Gene Therapy Alliance in X-Linked Chronic Granulomatous Disease
X-linked CGD is a primary immune deficiency resulting from a mutation on the X-chromosome and affecting mainly boys.
Orchard today announced the opening of a second facility for technical operations in the San Francisco Bay Area.
Orchard Therapeutics Announces Extension of its Collaboration with Manchester University to Include Sanfilippo Syndrome Type B
Orchard Therapeutics announces today that it has acquired an exclusive license to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B from The University of Manchester, UK.
Orchard Therapeutics Announces A Manufacturing Services Agreement With PCT Cell Therapy Services, LLC
Orchard Therapeutics And UCLA Receive $20 Million In Latest Round Of Funding From California's Stem Cell Agency
Orchard Therapeutics Announces Presentations From University College London/GOSH And UCLA Academic Collaborators On Clinical Data In ADA-SCID Using Ex-Vivo Lentiviral Gene Therapy At September 2016 ESID And ESGCT Congresses